Pfizer backs retina stem cell research

Article

Pfizer is to fund research into the application of stem cells in degenerative retinal disease through a $3 million investment in EyeCyte, a company based in California, US.

Pfizer is to fund research into the application of stem cells in degenerative retinal disease through a $3 million investment in EyeCyte, a company based in California, US.

EyeCyte, a spin-off of the laboratory of Professor Martin Friedlander, MD, PhD at the Scripps Research Institute, is currently investigating the role of stem and progenitor cells in the treatment of diabetic retinopathy. Other acquired and inherited retinal diseases the company is investigating include age-related macular degeneration, retinopathy of prematurity, retinal vascular occlusive disease and retinitis pigmentosa.

Professor Friedlander's research, funded by grants from the National Eye Institute (NEI) and the National Institutes of Health (NIH), has demonstrated that stem cells and progenitor cells can target neovascularization and halt the degeneration of the vasculature in animal models.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Jay Chhablani, MD, shares late-breaking data from the ArMaDa trial, investigating gene therapy for Geographic Atrophy and dry age-related macular degeneration, at EURETINA
Editorial advisory board member Alexandra Miere, MD, PhD, speaks about the ACTOR and HERMES studies at the 2025 European Society of Retina Specialists (EURETINA) Congress
María Berrocal, MD, speaks about the Vit-Buckle Society symposium hosted at the 2025 European Society of Retina Specialists (EURETINA) annual meeting
© 2025 MJH Life Sciences

All rights reserved.